Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. Martelli M, et al. Among authors: lauta vm. J Clin Oncol. 2003 Apr 1;21(7):1255-62. doi: 10.1200/JCO.2003.01.117. J Clin Oncol. 2003. PMID: 12663712 Clinical Trial.
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S. Zinzani PL, et al. Among authors: lauta vm. Blood. 1997 Jun 1;89(11):3974-9. Blood. 1997. PMID: 9166835 Free article. Clinical Trial.
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Zinzani PL, et al. Among authors: lauta vm. Blood. 1999 Jul 1;94(1):33-8. Blood. 1999. PMID: 10381495 Free article. Clinical Trial.
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Zinzani PL, et al. Among authors: lauta vm. J Clin Oncol. 2000 Feb;18(4):773-9. doi: 10.1200/JCO.2000.18.4.773. J Clin Oncol. 2000. PMID: 10673518 Clinical Trial.
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Zinzani PL, et al. Among authors: lauta vm. Ann Oncol. 2002 Sep;13(9):1364-9. doi: 10.1093/annonc/mdf208. Ann Oncol. 2002. PMID: 12196361 Free article. Clinical Trial.
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Zinzani PL, et al. Among authors: lauta vm. J Clin Oncol. 2004 Jul 1;22(13):2654-61. doi: 10.1200/JCO.2004.07.170. Epub 2004 May 24. J Clin Oncol. 2004. PMID: 15159414 Clinical Trial.
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Zinzani PL, et al. Among authors: lauta vm. Haematologica. 1999 Nov;84(11):996-1001. Haematologica. 1999. PMID: 10553159 Clinical Trial.
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Tura S, Papa G. Stasi R, et al. Among authors: lauta vm. Cancer. 1994 Sep 15;74(6):1792-800. doi: 10.1002/1097-0142(19940915)74:6<1792::aid-cncr2820740623>3.0.co;2-f. Cancer. 1994. PMID: 8082082
37 results